Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination with Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

Investigator: David Baskin, MD

Study Coordinator: Melissa Daly

Status: Enrolling Number: NCT03596086

Phone: 713.441.3834

Protocol Number: Pro00016414


NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma multiforme. This study is comprised of patients who have failed initial standard of care treatment (maximal safe resection followed by chemoradiation) and whose tumors have recurred. Patients who have enrolled in a previous gene vector study can enroll onto this protocol once progression has been documented, as long as a reoperation is performed and tissue diagnosis is confirmed at the new surgery.
More to Explore